It has been used to treat chronic [[psoriasis vulgaris]]<ref>{{cite journal |pmid=6339290 |year=1983 |last1=Galbiati |first1=G |last2=Bonfacini |first2=V |last3=Candiani |first3=F |title=Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris |volume=11 Suppl 1 |pages=31–3 |journal=The Journal of International Medical Research}}</ref> and non-infected acute eczematous dermatoses ([[eczema]]).<ref>{{cite journal |pmid=6339286 |year=1983 |last1=Yawalkar |first1=SJ |last2=MacArol |first2=V |last3=Montanari |first3=C |title=An overview of international clinical trials with halometasone cream |volume=11 Suppl 1 |pages=1–7 |journal=The Journal of International Medical Research}}</ref> One study demonstrated that 0.05% halometasone cream was more effective than 0.05% [[betamethasone]] cream in treating dermatitis, though both were well-tolerated with no systemic adverse effects reported.<ref>{{cite journal |pmid=6342285 |year=1983 |last1=Schuppli |first1=R |last2=Dressler |first2=H |last3=Yawalkar |first3=SJ |last4=Weirich |first4=EG |title=Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate |volume=58 |issue=4 |pages=230–7 |journal=Zeitschrift für Hautkrankheiten}}</ref>
